iBio, Inc. Form 10-Q Summary
Business context and reporting period
iBio is a biotechnology company commercializing plant-based protein expression technologies, developing biopharmaceutical candidates, and providing development and manufacturing services. The filing covers the quarter and six months ended December 31, 2016, the second quarter of fiscal 2017. iBio operated through its core business and majority-owned iBio CMO subsidiary, which began commercial operations in January 2016.
Financial performance and position
| Metric | Three months ended Dec. 31, 2016 | Six months ended Dec. 31, 2016 |
|---|---|---|
| Revenue | $75,000 | $210,000 |
| Operating loss | $3.325 million | $6.479 million |
| Consolidated net loss | $3.792 million | $7.404 million |
| Net loss attributable to iBio | $3.229 million | $6.290 million |
| Loss per share | $0.04 | $0.07 |
| Cash used in operating activities | Not separately provided | $5.837 million |
Calculated operating margins were approximately negative 4,433% for the quarter and negative 3,085% for the six-month period. Calculated net margins attributable to iBio were approximately negative 4,305% and negative 2,995%, respectively. These percentages reflect the company’s very limited revenue base.
- Research and development expense was $1.049 million for the quarter and $1.869 million for the six months.
- General and administrative expense was $2.351 million for the quarter and $4.820 million for the six months.
- Interest expense was $483,000 for the quarter and $966,000 for the six months, primarily related to the iBio CMO capital lease.
- Cash was $16.329 million at December 31, 2016, compared with $23.014 million at June 30, 2016.
- Total assets were $44.188 million and total liabilities were $27.042 million at December 31, 2016.
- The capital lease obligation was $25.351 million, including $176,000 current and $25.175 million long term. The underlying 34-year sublease requires base rent of approximately $2.1 million annually, subject to increases.
- Accumulated deficit was $63.881 million. iBio stockholders’ equity was $4.153 million, and noncontrolling interest was $12.993 million.
- Fixed assets, primarily related to iBio CMO, were $25.453 million, and intangible assets were $1.960 million.
Material changes versus the prior comparable period
- Quarterly revenue declined 44% to $75,000 from $134,000; six-month revenue declined 29% to $210,000 from $294,000. Revenue primarily reflected technology services for the Fiocruz yellow fever vaccine program and was recognized with an equivalent subcontractor research expense, producing no profit on that activity.
- Quarterly operating loss increased to $3.325 million from $2.254 million, while the six-month operating loss increased to $6.479 million from $4.067 million.
- Quarterly net loss attributable to iBio increased to $3.229 million from $2.246 million; six-month loss increased to $6.290 million from $4.051 million.
- Research and development expense increased by $345,000 for the quarter and $614,000 for the six months, primarily because of iBio CMO operations.
- General and administrative expense increased by $667,000 for the quarter and $1.714 million for the six months, primarily because of iBio CMO operations.
- Interest expense increased from zero in the prior-year periods to $483,000 for the quarter and $966,000 for the six months because of the iBio CMO capital lease.
- Cash used in operating activities increased to $5.837 million from $2.814 million for the comparable six-month period. Investing cash use increased to $765,000 from $5,000, including $226,000 of intangible asset additions and $539,000 of fixed-asset purchases.
- iBio CMO generated $49,000 of external revenue during the six months and no external revenue during the quarter; the prior-year comparable periods had no iBio CMO external revenue.
Outlook, risks, contingencies, and unusual items
- Management stated that the $16.3 million of cash on hand was expected to support activities at least through December 31, 2017, but also indicated that additional capital may be needed to fully implement plans beyond June 30, 2017.
- The company expects to fund operations through cash on hand, additional equity or other securities, licensing and collaboration arrangements, and iBio CMO operations. No shares had been sold under the $15 million Aspire Capital facility as of the filing date.
- Future equity financing could materially dilute existing stockholders. Management warned that inability to obtain financing could require delaying, reducing, or discontinuing development and commercialization activities, disposing of technology rights, or ceasing operations.
- iBio CMO is a 70%-owned joint venture with an Eastern affiliate, which contributed $15 million for a 30% interest. Eastern also purchased 10 million iBio shares and exercised warrants, resulting in approximately 38% beneficial ownership, subject to a standstill arrangement.
- The company is developing IBIO-CFB03 for fibrotic diseases and had an amended license milestone requiring an IND filing by June 30, 2017. Failure to meet contractual or regulatory milestones could affect the related licensed technology.
- iBio prevailed on a threshold ownership issue in its litigation against Fraunhofer, but the litigation remained unresolved and the company stated that it could not predict the outcome.
- A putative derivative action was subject to a proposed settlement awaiting final court approval. The company expected insurance to fund the settlement.
- The company has incurred recurring losses and negative operating cash flow since its 2008 spin-off. Its financial statements were prepared on a going-concern basis, and the filing identifies substantial dependence on future financing and commercialization efforts.
- No income tax expense was recorded because the company continued to maintain a full valuation allowance against its deferred tax assets.
Important facts for investors to verify
- Whether iBio CMO can generate sufficient third-party manufacturing, development, and technology-transfer revenue to offset its substantial lease, operating, and development costs.
- The actual cash-burn rate after December 31, 2016 and the timing and terms of any required financing.
- Progress toward the June 30, 2017 IND milestone for the fibrosis program.
- The status and potential financial impact of the Fraunhofer litigation and the proposed derivative-action settlement.
- Whether the 34-year iBio CMO lease obligation and minimum annual rent requirements remain commercially supportable.
- Potential dilution from future equity issuance, including use of the Aspire Capital facility and the company’s broader shelf registration.
- The filing’s reported segment revenue, particularly the limited external revenue from iBio CMO and continued dependence on the Fiocruz program.